Eli Lilly (LLY 0.15%) has been experiencing fantastic growth due to the success of its GLP-1 drugs, Mounjaro (approved for diabetes) and Zepbound (approved for weight loss). But the bigger catalyst that investors are eagerly awaiting is the approval of the company's weight loss pill, orforglipron. Nonetheless, shares of Eli Lilly were down slightly on the news, especially with rival Novo Nordisk already obtaining approval for its GLP-1 pill and experiencing strong demand out of the gate. The public has shown that what matters more is having access to a safe, effective, and affordable weight loss treatment; any first-mover advantage is likely to be minimal. Eli Lilly is an excellent long-term holding, and if there does prove to be a prolonged dip in value, it could simply create a terrific buying opportunity.